KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Long-Term Investments (2018 - 2025)

Takeda Pharmaceutical (TAK) has 7 years of Long-Term Investments data on record, last reported at $70.8 million in Q1 2025.

  • For Q1 2025, Long-Term Investments fell 88.32% year-over-year to $70.8 million; the TTM value through Mar 2025 reached $70.8 million, down 88.32%, while the annual FY2025 figure was $70.9 million, 88.62% down from the prior year.
  • Long-Term Investments reached $70.8 million in Q1 2025 per TAK's latest filing, down from $606.2 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $2.2 billion in Q1 2021 and bottomed at $70.8 million in Q1 2025.
  • Average Long-Term Investments over 4 years is $934.1 million, with a median of $718.6 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: skyrocketed 126.06% in 2021, then plummeted 88.32% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $2.2 billion in 2021, then crashed by 62.71% to $831.0 million in 2022, then fell by 27.06% to $606.2 million in 2024, then tumbled by 88.32% to $70.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $70.8 million in Q1 2025, $606.2 million in Q1 2024, and $831.0 million in Q1 2022.